Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: P53 expression as a predictor of recurrence in cervical squamous cell carcinoma
Author: Brenna, SMF
Zeferino, LC
Pinto, GA
Souza, RA
Andrade, LAL
Vassalo, J
Martinez, EZ
Syrjanen, KJ
Abstract: P53 protein function is frequently down-regulated in cervical cancer by complexing with human papillomavirus (HPV) E6 protein, leading to degradation of p53, genomic instability, and mutations. Results are controversial, however, on the prognostic value of p53 protein expression in cervical cancer. In this study, a cohort of 220 Brazilian women with FIGO stage IB-III cervical squamous cell carcinoma (SCC), followed for 5 years, was analyzed for p53 protein expression using immunohistochemistry. The disease-free survival (DFS) and relapse rate were analyzed using univariate (Kaplan-Meier) and multivariable (Cox's proportional hazards model) survival analyses. P53 protein expression was detected in 35% of the patients, including 21% in stage I, 28% in stage II and 51% in stage III of disease. Of 220 women, only 116 completed one of the treatment options standardized by FIGO within 120 days. There was a higher risk of relapse in stage II and III disease, that was not modified by p53 positivity; HR 3.0 (1.3-6.5) to stage II and HR 4.0 (1.9-8.5) to stage III. The multivariate analysis evidenced that p53 expression is not an independent factor exceeding the power of FIGO stage as the single most important determinant of the hazards for disease relapse.
Subject: cervical cancer
tumor suppressor gene
Country: EUA
Editor: Blackwell Publishing Inc
Citation: International Journal Of Gynecological Cancer. Blackwell Publishing Inc, v. 12, n. 3, n. 299, n. 303, 2002.
Rights: fechado
Identifier DOI: 10.1046/j.1525-1438.2002.01097.x
Date Issue: 2002
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000176131400010.pdf173.71 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.